What is B. Riley’s Forecast for AVBP Q1 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of ArriVent BioPharma in a note issued to investors on Wednesday, March 19th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.70) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.18.

A number of other research analysts also recently commented on AVBP. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of ArriVent BioPharma in a research report on Friday, March 7th. Guggenheim started coverage on shares of ArriVent BioPharma in a report on Monday, March 10th. They set a “buy” rating and a $45.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ArriVent BioPharma currently has a consensus rating of “Buy” and an average target price of $39.00.

ArriVent BioPharma Price Performance

Shares of AVBP opened at $18.99 on Monday. The business’s 50-day moving average is $24.70 and its 200-day moving average is $26.62. The company has a market capitalization of $645.96 million, a price-to-earnings ratio of -7.39 and a beta of 1.00. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Institutional Trading of ArriVent BioPharma

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in shares of ArriVent BioPharma by 153.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock valued at $4,756,000 after purchasing an additional 122,641 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in ArriVent BioPharma during the third quarter valued at about $240,000. FMR LLC lifted its position in shares of ArriVent BioPharma by 8.7% in the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after buying an additional 169,514 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ArriVent BioPharma by 32.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock worth $516,000 after acquiring an additional 5,397 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of ArriVent BioPharma by 168.9% during the 3rd quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after acquiring an additional 10,269 shares during the last quarter. 9.48% of the stock is owned by institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.